{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:52:25Z","timestamp":1784213545365,"version":"3.55.0"},"publisher-location":"Cham","reference-count":39,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030999940","type":"print"},{"value":"9783030999957","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/164_2021_561","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:49:48Z","timestamp":1642153788000},"page":"253-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["NAFLD and NASH: The Metabolically Diseased Liver"],"prefix":"10.1007","author":[{"given":"Angelo","family":"Armandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"561_CR1","doi-asserted-by":"crossref","unstructured":"Alqahtani SA, Schattenberg JM (2021) Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn:1\u201314","DOI":"10.1080\/14737159.2021.1964958"},{"issue":"6","key":"561_CR2","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/nu13061977","volume":"13","author":"A Armandi","year":"2021","unstructured":"Armandi A, Schattenberg JM (2021) Beyond the paradigm of weight loss in non-alcoholic fatty liver disease: from pathophysiology to novel dietary approaches. Nutrients 13(6):1977","journal-title":"Nutrients"},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679\u2013690","journal-title":"Lancet"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","volume":"19","author":"F Bazerbachi","year":"2021","unstructured":"Bazerbachi F, Vargas EJ, Rizk M et al (2021) Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19:146\u2013154 e144","journal-title":"Clin Gastroenterol Hepatol"},{"key":"561_CR5","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N et al (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751\u20131759","journal-title":"Hepatology"},{"key":"561_CR6","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297\u20132307","journal-title":"N Engl J Med"},{"key":"561_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165:305\u2013315","journal-title":"Ann Intern Med"},{"issue":"4","key":"561_CR8","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/hep.31869","volume":"74","author":"AM Dinani","year":"2021","unstructured":"Dinani AM, Kowdley KV, Noureddin M (2021) Application of artificial intelligence for diagnosis and risk stratification in NAFLD and NASH: the state of the art. Hepatology 74(4):2233\u20132240","journal-title":"Hepatology"},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/jamia\/ocab003","volume":"28","author":"M Docherty","year":"2021","unstructured":"Docherty M, Regnier SA, Capkun G et al (2021) Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. J Am Med Inform Assoc 28:1235\u20131241","journal-title":"J Am Med Inform Assoc"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557\u20131565","journal-title":"Hepatology"},{"key":"561_CR11","first-page":"1388","volume":"64","author":"EASL","year":"2016","unstructured":"EASL (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388\u20131402","journal-title":"J Hepatol"},{"issue":"3","key":"561_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"EASL","year":"2021","unstructured":"EASL (2021) EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2020 update. J Hepatol 75(3):659\u2013689","journal-title":"J Hepatol"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.jhepr.2021.100317","volume":"3","author":"E Erhardtsen","year":"2021","unstructured":"Erhardtsen E, Rasmussen DGK, Frederiksen P et al (2021) Determining a healthy reference range and factors potentially influencing PRO-C3 \u2013 a biomarker of liver fibrosis. JHEP Rep 3:100317","journal-title":"JHEP Rep"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209","journal-title":"J Hepatol"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69:896\u2013904","journal-title":"J Hepatol"},{"key":"561_CR16","doi-asserted-by":"publisher","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","volume":"98","author":"SM Francque","year":"2020","unstructured":"Francque SM, Bedossa P, Abdelmalek MF et al (2020) A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. Contemp Clin Trials 98:106170","journal-title":"Contemp Clin Trials"},{"key":"561_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","volume":"72","author":"G Garcia-Tsao","year":"2020","unstructured":"Garcia-Tsao G, Bosch J, Kayali Z et al (2020) Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol 72:885\u2013895","journal-title":"J Hepatol"},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/cd18-0026","volume":"37","author":"P Golabi","year":"2019","unstructured":"Golabi P, Paik J, Fukui N et al (2019) Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes 37:65\u201372","journal-title":"Clin Diabetes"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","volume":"152","author":"D Goldberg","year":"2017","unstructured":"Goldberg D, Ditah IC, Saeian K et al (2017) Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152:1090\u20131099 e1091","journal-title":"Gastroenterology"},{"key":"561_CR20","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394:2012\u20132024","journal-title":"Lancet"},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Goodman Z, Jabbar A et al (2020) A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol 72:816\u2013827","journal-title":"J Hepatol"},{"key":"561_CR22","doi-asserted-by":"publisher","first-page":"102706","DOI":"10.1016\/j.autrev.2020.102706","volume":"20","author":"MA Karsdal","year":"2021","unstructured":"Karsdal MA, Kraus VB, Shevell D et al (2021) Profiling and targeting connective tissue remodeling in autoimmunity \u2013 a novel paradigm for diagnosing and treating chronic diseases. Autoimmun Rev 20:102706","journal-title":"Autoimmun Rev"},{"key":"561_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 41:1801\u20131808","journal-title":"Diabetes Care"},{"key":"561_CR24","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji LC et al (2020) Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159:1290\u20131301 e1295","journal-title":"Gastroenterology"},{"issue":"10","key":"561_CR1001","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","volume":"18","author":"JV Lazarus","year":"2021","unstructured":"Lazarus JV, Anstee QM, Hagstr\u00f6m H et al (2021) Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 18(10):717\u2013729","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"561_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","volume":"68","author":"R Loomba","year":"2018","unstructured":"Loomba R (2018) Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol 68:296\u2013304","journal-title":"J Hepatol"},{"key":"561_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124","journal-title":"N Engl J Med"},{"key":"561_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hep.31777","volume":"74","author":"M Noureddin","year":"2021","unstructured":"Noureddin M (2021) Artificial intelligence in NASH histology: human teaches a machine for the machine to help humans. Hepatology 74:9\u201311","journal-title":"Hepatology"},{"key":"561_CR28","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/liv.14441","volume":"40","author":"F Salomone","year":"2020","unstructured":"Salomone F, Sharaiha RZ, Boskoski I (2020) Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives. Liver Int 40:1262\u20131268","journal-title":"Liver Int"},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675\u20131685","journal-title":"N Engl J Med"},{"key":"561_CR30","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V et al (2019) The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70:1913\u20131927","journal-title":"Hepatology"},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/liv.14825","volume":"41","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, Lazarus JV, Newsome PN et al (2021) Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int 41:1227\u20131242","journal-title":"Liver Int"},{"key":"561_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","volume":"68-69","author":"D Schuppan","year":"2018","unstructured":"Schuppan D, Ashfaq-Khan M, Yang AT et al (2018) Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol 68-69:435\u2013451","journal-title":"Matrix Biol"},{"key":"561_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali Y, Lee J, Boursier J et al (2020) Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 73:252\u2013262","journal-title":"J Hepatol"},{"key":"561_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease \u2013 meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73\u201384","journal-title":"Hepatology"},{"key":"561_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"561_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L et al (2019a) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71:793\u2013801","journal-title":"J Hepatol"},{"issue":"10215","key":"561_CR37","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R et al (2019b) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394(10215):2184\u20132196","journal-title":"Lancet"},{"key":"561_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3109\/00365521.2012.719926","volume":"48","author":"H Zhang","year":"2013","unstructured":"Zhang H, Gao C, Fang L et al (2013) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 48:78\u201387","journal-title":"Scand J Gastroenterol"}],"container-title":["Handbook of Experimental Pharmacology","From Obesity to Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2021_561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T14:34:38Z","timestamp":1658414078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2021_561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030999940","9783030999957"],"references-count":39,"URL":"https:\/\/doi.org\/10.1007\/164_2021_561","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"23 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}